Loading...
Docoh
Log in Free sign up

BioCardia (BCDA)

BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company's biotherapeutic platforms in clinical development. The Company's products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia, and acute myocardial infarction.

Company profile

Ticker
BCDA, BCDAW
Exchange
NASDAQ
Website
www.biocardia.com
CEO
Peter Altman
Employees
Incorporated
Delaware
Location
California
Fiscal year end
Dec 31
Sector
Manufacturing > Surgical and Medical Instrument Manufacturing
Industry (SIC)
Biological Products, (No Diagnostic Substances)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne ...
Former names
Cardo Medical, Inc., CLICKNSETTLE COM INC, NAM CORP, Tiger X Medical, Inc.
SEC CIK
0000925741
Corporate docs
Subsidiaries
BioCardia Lifesciences, Inc. ...
IRS number
232753988

BCDA stock data

News

From Benzinga Pro
Recap: BioCardia Q2 Earnings
10 Aug 22
BioCardia (NASDAQ:BCDA) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
BioCardia Q2 EPS $(0.14) Beats $(0.25) Estimate, Sales $974.00K Up From $69.00K YoY
10 Aug 22
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.25) by 44 percent. This is a 30 percent increase over losses of $(0.20) per share from the same
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
10 Aug 22
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For August 10, 2022
10 Aug 22
BioCardia Earnings Preview
9 Aug 22

Press releases

From Benzinga Pro
BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022
4 Aug 22
SUNNYVALE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today
BioCardia to Participate in Upcoming Heart and Pulmonary Therapy Development Symposia
12 Jul 22
SUNNYVALE, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), Sunnyvale, Calif. – BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment
Thinking about buying stock in BioCardia, Boxed, Zomedica, New Oriental Education, or Garrett Motion?
15 Jun 22
NEW YORK, June 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BCDA, BOXD, ZOM, EDU, and GTX.

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

10 Aug 22
16 Aug 22
31 Dec 22

Financial summary

Financial statements Chart BCDA financial data
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 8.61M 8.61M 8.61M 8.61M 8.61M 8.61M
Cash burn (monthly) 438.67K 827.42K 832K 999.33K 881.67K 931.33K
Cash used (since last report) 688.52K 1.3M 1.31M 1.57M 1.38M 1.46M
Cash remaining 7.93M 7.32M 7.31M 7.05M 7.23M 7.15M
Runway (months of cash) 18.1 8.8 8.8 7.1 8.2 7.7

Beta Read what these cash burn values mean

Financial data from BioCardia earnings reports.

Recent insider trades

BCDA insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
10 Jun 22 Altman Peter Common Stock Buy Acquire P No No 1.46 4,500 6.57K 321,197
13 May 22 Altman Peter Common Stock Buy Acquire P No No 1.38 2,698 3.72K 348,143
12 May 22 Altman Peter Common Stock Payment of exercise Dispose F No No 1.32 31,446 41.51K 316,697
12 May 22 Edward M Gillis Common Stock Payment of exercise Dispose F No No 1.32 12,358 16.31K 23,879
12 May 22 McClung David Common Stock Payment of exercise Dispose F No No 1.32 20,632 27.23K 76,518
12 May 22 Altman Peter Common Stock Buy Acquire P No No 1.2 11,302 13.56K 345,445
11 May 22 Altman Peter Common Stock Buy Acquire P No No 1.3 1,000 1.3K 334,143
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

BCDA institutional ownership history Ownership history
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Abbott Laboratories • Caladrius Biosciences • Gene Biotherapeutics • ThermoGenesis • Vericel • Plus Therapeutics • Capricor Therapeutics • Mesoblast • Athersys • VistaGen Therapeutics

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: Ambulatory, awaiting, CCS, certified, cleanroom, echocardiography, Exemption, fluoroscopy, formal, fulfilled, fulfilment, futility, Institute, ISO, Japan, July, mononuclear, Ottawa, passage, payment, Pharmaceutical, PMDA, recovery, rehospitalization, relapse, respirator, retroactive, scheduled, survival, sustained, transthoracic, ultrasound, York
Removed: coupled
From filing 10-Q 2022 Q2
Financial reports
View all
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
10-K
2021 FY
Annual report
29 Mar 22
10-Q
2021 Q3
Quarterly report
10 Nov 21
10-Q
2021 Q2
Quarterly report
12 Aug 21
10-Q
2021 Q1
Quarterly report
13 May 21
10-K
2020 FY
Annual report
30 Mar 21
10-Q
2020 Q3
Quarterly report
10 Nov 20
10-Q
2020 Q2
Quarterly report
13 Aug 20
10-Q
2020 Q1
Quarterly report
15 May 20
Current reports
View all
8-K
Biocardia Reports Second Quarter 2022 Business Highlights and Financial Results
10 Aug 22
8-K
BioCardia Announces First Canadian Clinical Site for CardiAMP Cell Therapy Heart Failure Trial
1 Aug 22
8-K
BioCardia Announces US Patent on Imaging System for Targeting Cardiac Therapies
15 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
10 Jun 22
8-K
Biocardia Reports First Quarter 2022 Business Highlights and Financial Results
11 May 22
8-K
Other Events
12 Apr 22
8-K
Phase I/II Trial Initiation Expected in 3Q 2022
12 Apr 22
8-K
Biocardia Reports 2021 Financial Results and Recent Business Highlights
29 Mar 22
8-K
BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure
22 Mar 22
8-K
BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada
1 Mar 22
Registration and prospectus
View all
424B5
Prospectus supplement for primary offering
12 Apr 22
S-8
Registration of securities for employees
30 Mar 22
S-8
Registration of securities for employees
30 Mar 21
424B5
Prospectus supplement for primary offering
29 Mar 21
424B5
Prospectus supplement for primary offering
16 Dec 20
424B5
Prospectus supplement for primary offering
15 Dec 20
S-3
Shelf registration
9 Oct 20
424B4
Prospectus supplement with pricing info
18 Jun 20
S-1/A
IPO registration (amended)
15 Jun 20
FWP
Free writing prospectus
8 Jun 20
Proxies
View all
DEF 14A
Definitive proxy
27 Apr 22
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEF 14A
Definitive proxy
30 Apr 21
DEF 14A
Definitive proxy
1 Dec 20
PRE 14A
Preliminary proxy
20 Nov 20
DEFA14A
Additional proxy soliciting materials
15 Oct 19
DEF 14A
Definitive proxy
15 Oct 19
PRE 14A
Preliminary proxy
4 Oct 19
DEF 14C
Information statement
16 Apr 19
PRE 14C
Preliminary information
5 Apr 19
Other
View all
EFFECT
Notice of effectiveness
21 Oct 20
CORRESP
Correspondence with SEC
18 Oct 20
UPLOAD
Letter from SEC
14 Oct 20
EFFECT
Notice of effectiveness
17 Jun 20
CORRESP
Correspondence with SEC
14 Jun 20
CORRESP
Correspondence with SEC
14 Jun 20
EFFECT
Notice of effectiveness
22 Apr 20
UPLOAD
Letter from SEC
19 Feb 20
UPLOAD
Letter from SEC
16 Dec 19
CORRESP
Correspondence with SEC
4 Dec 19
Ownership
View all
4
BioCardia / Peter Altman ownership change
13 Jun 22
4
BioCardia / Peter Altman ownership change
18 May 22
4
BioCardia / EDWARD M GILLIS ownership change
18 May 22
4
BioCardia / David McClung ownership change
18 May 22
4
BioCardia / Peter Altman ownership change
13 May 22
4
BioCardia / Peter Altman ownership change
2 May 22
4
BioCardia / Peter Altman ownership change
18 Apr 22
4
BioCardia / David McClung ownership change
18 Apr 22
4
BioCardia / EDWARD M GILLIS ownership change
18 Apr 22
SC 13G/A
BioCardia / Francis Capital Management ownership change
14 Feb 22

Patents

View all
Utility
Target site selection, entry and update with automatic remote image annotation
14 Jun 22
Fluoroscopic imaging of a patient's heart is performed by positioning a patient in a sterile field and imaging the heart using a x-ray fluoroscopy system within the sterile to produce a two-dimensional image.
Utility
Multi-Directional Steerable Catheter
2 Jun 22
A bi-directional steerable catheter adapted for delivery into a patient's vasculature.
Utility
Target Site Selection, Entry and Update with Automatic Remote Image Annotation
14 Oct 21
Fluoroscopic imaging of a patient's heart is performed by positioning a patient in a sterile field and imaging the heart using a x-ray fluoroscopy system within the sterile to produce a two-dimensional image.
Utility
Multi-directional steerable catheter
12 Oct 21
A bi-directional steerable catheter adapted for delivery into a patient's vasculature.
Utility
Methods of Measuring Potential for Therapeutic Potency and Defining Dosages for Autologous Cell Therapies
3 Jun 21
Autologous bone marrow cells (BMC) are transplanted to a heterologous site in a patient after a sample of the patient's BMC has been tested and found to have a phenotypic profile which meets minimum criteria for transplantation.

Transcripts

2022 Q2
Earnings call transcript
11 Aug 22
2022 Q1
Earnings call transcript
11 May 22
2021 Q4
Earnings call transcript
29 Mar 22

Reddit threads

View all